Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Matthew Langer Meyerson, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Matthew Meyerson and Andrew Cherniack.
Connection Strength

3.875
  1. Genomic and immune profiling of pre-invasive lung adenocarcinoma. Nat Commun. 2019 11 29; 10(1):5472.
    View in: PubMed
    Score: 0.225
  2. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Mol Cancer Res. 2019 11; 17(11):2281-2293.
    View in: PubMed
    Score: 0.221
  3. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun. 2018 12 21; 9(1):5450.
    View in: PubMed
    Score: 0.211
  4. Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet. 2018 07; 50(7):937-943.
    View in: PubMed
    Score: 0.204
  5. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 2018 04 09; 33(4):676-689.e3.
    View in: PubMed
    Score: 0.200
  6. Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. Cancer Discov. 2018 01; 8(1):108-125.
    View in: PubMed
    Score: 0.193
  7. Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2017 06 30; 7:46873.
    View in: PubMed
    Score: 0.190
  8. Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2016 06 24; 6:27960.
    View in: PubMed
    Score: 0.177
  9. Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2016 05 10; 6:25521.
    View in: PubMed
    Score: 0.176
  10. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016 06; 48(6):607-16.
    View in: PubMed
    Score: 0.176
  11. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat Genet. 2016 Feb; 48(2):176-82.
    View in: PubMed
    Score: 0.171
  12. Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7.
    View in: PubMed
    Score: 0.166
  13. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2014 Dec 30; 111(52):18661-6.
    View in: PubMed
    Score: 0.159
  14. Landscape of genomic alterations in cervical carcinomas. Nature. 2014 Feb 20; 506(7488):371-5.
    View in: PubMed
    Score: 0.149
  15. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. 2011 Dec 15; 71(24):7587-96.
    View in: PubMed
    Score: 0.128
  16. FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 Apr 29.
    View in: PubMed
    Score: 0.062
  17. Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. Cell Rep. 2021 Feb 02; 34(5):108707.
    View in: PubMed
    Score: 0.061
  18. Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clin Cancer Res. 2021 Mar 15; 27(6):1695-1705.
    View in: PubMed
    Score: 0.061
  19. Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics. 2020 Nov 28.
    View in: PubMed
    Score: 0.060
  20. Correction: Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. J Biol Chem. 2020 Nov 27; 295(48):16464-16467.
    View in: PubMed
    Score: 0.060
  21. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann Oncol. 2020 06; 31(6):807-814.
    View in: PubMed
    Score: 0.058
  22. Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. J Biol Chem. 2020 03 13; 295(11):3431-3446.
    View in: PubMed
    Score: 0.057
  23. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2018 08 09; 174(4):1033.
    View in: PubMed
    Score: 0.051
  24. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018 04 05; 173(2):321-337.e10.
    View in: PubMed
    Score: 0.050
  25. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19; 171(3):540-556.e25.
    View in: PubMed
    Score: 0.048
  26. Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer. Cancer Res. 2017 12 15; 77(24):6987-6998.
    View in: PubMed
    Score: 0.048
  27. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016 08 08; 30(2):363.
    View in: PubMed
    Score: 0.045
  28. Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016 08; 6(8):914-29.
    View in: PubMed
    Score: 0.044
  29. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016 05 09; 29(5):723-736.
    View in: PubMed
    Score: 0.044
  30. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016 Jan 28; 164(3):550-63.
    View in: PubMed
    Score: 0.043
  31. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14; 374(2):135-45.
    View in: PubMed
    Score: 0.042
  32. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25; 372(26):2481-98.
    View in: PubMed
    Score: 0.041
  33. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014 Sep 08; 26(3):319-330.
    View in: PubMed
    Score: 0.039
  34. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecol Oncol. 2014 Sep; 134(3):599-606.
    View in: PubMed
    Score: 0.039
  35. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013 Oct; 45(10):1134-40.
    View in: PubMed
    Score: 0.037
  36. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013 Dec; 3(12):1355-63.
    View in: PubMed
    Score: 0.037
  37. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science. 2013 May 31; 340(6136):1100-6.
    View in: PubMed
    Score: 0.036
  38. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 02; 497(7447):67-73.
    View in: PubMed
    Score: 0.036
  39. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A. 2011 Aug 16; 108(33):13379-86.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.